Navigation Links
Allied Healthcare Net Falls on Manufacturing Delays
Date:5/12/2008

Inc. is a leading manufacturer of respiratory care products, medical gas equipment and emergency medical products used in a wide range of alternate care settings.

"SAFE HARBOR" STATEMENT: Statements contained in this release that are not historical facts or information are "forward-looking statements." Words such as "believe," "expect," "intend," "will," "should," and other expressions that indicate future events and trends identify such forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the outcome and future results of operations and financial condition to be materially different than stated or anticipated based on the forward-looking statements. Such risks and uncertainties include both general economic risks and uncertainties, risks and uncertainties affecting the demand for and economic factors affecting the delivery of health care services, and specific matters which relate directly to the Company's operations and properties as discussed in its periodic filings with the Securities and Exchange Commission. The Company cautions that any forward-looking statement contained in this report reflects only the belief of the Company or its management at the time the statement was made. Although the Company believes such forward-looking statements are based upon reasonable assumptions, such assumptions may ultimately prove inaccurate or incomplete. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement was made.

ALLIED HEALTHCARE PRODUCTS, INC.

CONSOLIDATED STATEMENT OF OPERATIONS

(UNAUDITED)

Three months ended, Nine months ended,

March 31, March 31,

2008 2007 2008 2007 '/>"/>

SOURCE Allied Healthcare Products, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Allied Security Holdings LLC to Hold a Conference Call to Discuss Fiscal Year 2007 Results on Thursday, March 27, 2008 at 11:00 AM EDT
2. C.V. Starr & Company to Offer Management Liability Lines From Allied World Assurance Company
3. Allied Healthcares Net Suffers on Flat Sales, Performance Issues
4. Diana Hatsis of Chiltern Will Present at the Joint Commission on Allied Health Personnel in Ophthalmology (JCAHPO) 35th Annual Continuing Education Program Held in Conjunction With the American Academy of Ophthalmology (AAO) Annual Meeting
5. SIEMENS, AlliedBarton, Methodist Hospital, and Family Planning Council Win Human Resources Department of the Year Awards
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. 34 SEIU Healthcare Leaders Urge UHW-W Members to Join in Support of New Plan to Win Quality Healthcare for All, Build Strength of Healthcare Workers
8. Retiring Nurses See Healthcare Advocacy as Second Career - Healthcare Liaison Workshop June 7-8 Shows Them How to Make Transition
9. New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health
10. Cepheid Signs Group Purchasing Contract With Premier Healthcare Alliance, One of the Largest U.S. Group Purchasing Organizations
11. Watson to Present at the Bank of America 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2008)...ng point for behavior change, DES MOINES, Iowa, O...,Americans (51 percent) believe there are good thi...r changes are needed, according to the 2008,EBRI H...oday by the,Employee Benefit Research Institute an...derwritten by the Principal Financial Group(R)., ...
(Date:10/10/2008)...dentialing Center (ANCC) has designated Geisinger ...s came via a conference call to hospital administr...and applause., GMC joins an elite group of only 1...n the United States that have achieved Magnet stat...s recognition., "Achieving Magnet designation is ...
(Date:10/10/2008)... blame , , FRIDAY, Oct. 10 (HealthDay Ne...ve diabetes, being depressed was associated with a..., Publishing in the October issue of the Journal...he University of Washington tracked 10,704 Medicar...d diabetes and were enrolled in a disease manageme...
(Date:10/10/2008)...llence in the implementation of electronic health ...agement Systems Society (HIMSS) announces the reci...onal, Ambulatory and Community Health Organization...L (PRWEB) October 10, 2008 -- Honoring excellence ... (EHRs), the Healthcare Information and Managemen...
Breaking Medicine News(10 mins):Health News:Video: Just What the Doctor Ordered: Survey Shows Americans Adopting Healthier Lifestyles 2Health News:Video: Just What the Doctor Ordered: Survey Shows Americans Adopting Healthier Lifestyles 3Health News:Geisinger Medical Center earns prestigious Magnet designation 2Health News:Older Diabetics With Depression Face Higher Death Rate 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 3Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 4Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 5
...a routine dental check-up may not only prevent the...nalysis says that such screenings could end up sav...in healthcare costs for the patients. The review ...alth Technology Assessment, the international jour...
... are pretty much of a household therapy in the Uni...has revealed that these therapies have added value...ing the quality of life. In that respect, United K... health investment. “The conclusion is that if yo...
...at the University of California, San Francisco (UC... prevents the growth of brain cancer. // The compo...ate against lethal brain tumor. In animal studies ... to be potent against proliferating cancer cells. ...
... when uou're 80 years old or more might be quite b...s from a joint UC Irvine and University of Souther... mortality rates from participants of a large-scal... California retirement community. The analysis fo...
Other Medicine News:Health News:Routine Dental Check-Ups Should Include Oral Cancer Screening 2Health News:Varicose Vein Treatments Turn Out To Be A Viable Health Investment 2Health News:Varicose Vein Treatments Turn Out To Be A Viable Health Investment 3Health News:PI-103 Effective against Brain Cancer 2Health News:PI-103 Effective against Brain Cancer 3Health News:Elderly and Overweight -Not Such a Bad Combination After All 2
(Date:10/8/2008)...e, Oct. 8 /- Vical Incorporated (Nasd...data and new nonclinical data,demonstrating that t...applicable in DNA- and protein-based infectious di...Alain P. Rolland, Pharm.D., Ph.D., Vical,s,Senior ...t the data today,Wednesday, October 8, at the Wor...
(Date:10/7/2008)...as, Oct. 7 /- The Texas Cardiac Arrhy...er has been selected as one of,only a few sites in...ical,trial for a new device to treat persistent at...t, training and research center specializing in he... David,s Medical Center and,Texas Cardiovascular C...
(Date:10/7/2008)...al study of adults, VYVANSE taken once-daily signi...week, PHILADELPHIA, Oct. 7 /PRNewswire-FirstCall/...l specialty biopharmaceutical company, today,annou... of the Journal of,Clinical Psychiatry found once-...icit Hyperactivity Disorder (ADHD) symptoms in adu...
(Date:10/7/2008)...tracts highlighting CIMZIA,s long-term benefits an...ents presented at American College,of Gastroentero...tCall/ -- Data from two studies,presented this wee...gy,(ACG) Annual Meeting demonstrate that CIMZIA(R)...F alpha (Tumor Necrosis Factor alpha) - provides,s...
Breaking Medicine Technology:Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Texas Cardiac Arrhythmia Institute at St. David's Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9New study sheds light on Gal 26 23225 3Bpagos hawk evolutionary history 641 1New study sheds light on Gal 26 23225 3Bpagos hawk evolutionary history 641 2First significant genetic finding in severe PMS or PMDD 2600 1First significant genetic finding in severe PMS or PMDD 2600 2Algorithms to reanimate the heart 2598 1Algorithms to reanimate the heart 2598 2Algorithms to reanimate the heart 2598 3Dietary calcium could possibly prevent the spread of breast cancer to bone 639 1Dietary calcium could possibly prevent the spread of breast cancer to bone 639 2
...SINESS WIRE)--Jun 25, 2007 - Neurogen,Corporation ...esults from two dose-ranging, Phase 2b clinical tr...,s proprietary insomnia agent,NG2-73, an alpha-3 ...lations were studied in each trial to determine th...ntenance of sleep,through the night without residu...
...hly potent DPP-4 inhibitor, possessing Ki of 27,pM...armaceuticals,Inc., a privately held drug discove...results of its potent, smart DPP-4 inhibitor,ARI-...n Diabetes,Association meeting in Chicago, Illinoi...y long acting, potent inhibitor of DPP-4 and,produ...
Other Medicine Technology:Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 2Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 3Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 4Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 5Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 6Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 7Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 8Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4,Inhibitor, ARI-2243, at the ADA 2Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4,Inhibitor, ARI-2243, at the ADA 3Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4,Inhibitor, ARI-2243, at the ADA 4
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl
...B®) Test is a clinical chemistry assay that de...uring the cobalt binding capacity of albumin in a ...y 1990s, IMA is produced when circulating albumin .... During ischemia, the N-terminus of albumin is al...
...une testing feature single-well ANA screen and ENA...ncluding dsDNA, and 6 individual ENA kits: Sm, Sm/...ition, our autoimmune ELISA family includes a full..., Thyroglobulin, Thyroid Microsomal, MPO, PR3, Rhe...
... Diagnostics is a leading provider of immunofluore...menu that includes kits for autoimmune diseases, i...us conjugates and components. Our Impact IFA Test ...nd kit sizes to choose from. Kit components includ...
Medicine Products: